193 related articles for article (PubMed ID: 31508900)
21. Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database.
Chikamatsu S; Shiota M; Onozawa M; Hinotsu S; Kitagawa Y; Sakamoto S; Kawai T; Eto M; Kume H; Akaza H;
Int J Urol; 2021 Sep; 28(9):927-935. PubMed ID: 34028097
[TBL] [Abstract][Full Text] [Related]
22. Impact of nutritional status on the prognosis of patients with metastatic hormone-naïve prostate cancer: a multicenter retrospective cohort study in Japan.
Okamoto T; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
World J Urol; 2019 Sep; 37(9):1827-1835. PubMed ID: 30511214
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
24. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C
Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
[TBL] [Abstract][Full Text] [Related]
25. Survival following primary androgen deprivation therapy for localized intermediate- or high-risk prostate cancer: comparison with the life expectancy of the age-matched normal population.
Matsumoto K; Hagiwara M; Tanaka N; Hayakawa N; Ishida M; Ninomiya A; Nakajima Y; Nakamura S
Med Oncol; 2014 Jun; 31(6):979. PubMed ID: 24781338
[TBL] [Abstract][Full Text] [Related]
26. Retrospective validation of bone risk stratification criteria for men with de novo metastatic hormone-naive prostate cancer in China.
Zhang Y; Ding L; Zheng Y; Wang K; Xia W; Wang J; Ge P
PeerJ; 2023; 11():e14500. PubMed ID: 36624752
[TBL] [Abstract][Full Text] [Related]
27. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
28. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
29. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
30. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Martin NE; Orio PF; Mouw KW; King MT; Choueiri TK; Trinh QD; Hoffman KE; Spratt DE; Feng FY; Nguyen PL
Eur Urol; 2019 Jan; 75(1):35-41. PubMed ID: 30554605
[TBL] [Abstract][Full Text] [Related]
31. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy.
Qian Y; Feng FY; Halverson S; Blas K; Sandler HM; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e135-42. PubMed ID: 21345617
[TBL] [Abstract][Full Text] [Related]
32. Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With
Kobayashi T; Namitome R; Hirata YU; Shiota M; Imada K; Kashiwagi E; Takeuchi A; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2019 Jun; 39(6):3191-3195. PubMed ID: 31177166
[TBL] [Abstract][Full Text] [Related]
33. American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.
Keyes M; Merrick G; Frank SJ; Grimm P; Zelefsky MJ
Brachytherapy; 2017; 16(2):245-265. PubMed ID: 28110898
[TBL] [Abstract][Full Text] [Related]
34. Very high-risk prostate cancer: stratification by outcomes of radiotherapy and long-term androgen deprivation therapy.
Tomita N; Soga N; Ogura Y; Kageyama T; Kodaira T
Asia Pac J Clin Oncol; 2017 Jun; 13(3):145-151. PubMed ID: 28124495
[TBL] [Abstract][Full Text] [Related]
35. Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naïve bone-metastatic prostate cancer.
Ebbinge M; Berglund A; Varenhorst E; Hedlund PO; Sandblom G;
BJU Int; 2018 Oct; 122(4):583-591. PubMed ID: 29611275
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer.
Nagata Y; Matsukawa T; Tomisaki I; Fujimoto N
Anticancer Res; 2022 Feb; 42(2):1107-1114. PubMed ID: 35093913
[TBL] [Abstract][Full Text] [Related]
37. Gleason score 7 prostate cancer treated with interstitial brachytherapy with or without supplemental external beam radiation and androgen deprivation therapy: is the primary pattern on needle biopsy prognostic?
Bittner N; Merrick GS; Butler WM; Galbreath RW; Adamovich E; Wallner KE
Brachytherapy; 2013; 12(1):14-8. PubMed ID: 22884256
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer.
Morgan SC; Holmes OE; Craig J; Grimes S; Malone S
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1041-1047. PubMed ID: 33820949
[TBL] [Abstract][Full Text] [Related]
39. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy.
Taira AV; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1143-9. PubMed ID: 19117691
[TBL] [Abstract][Full Text] [Related]
40. Survival and prognostic determinants of prostate cancer patients in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A retrospective cohort study.
Beksisa J; Getinet T; Tanie S; Diribi J; Hassen HY
PLoS One; 2020; 15(3):e0229854. PubMed ID: 32134996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
